Type 2 diabetes: CHMP recommends empagliflozin/metformin hydrochloride for approval in the EU

Empagliflozin when added to metformin HCl lowers blood glucose, body weight and blood pressure. Side effects identified with empagliflozin plus metformin HCl were in line with the known safety profile of the individual compounds empagliflozin and metformin.

Source: Pharmacy Europe - March 30, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Diabetes Patient care blood pressure body weight empagliflozin/metformin HCl Latest News safety profile type 2 diabetes Source Type: news